Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...
Business Insider1h
Promising Pipeline Developments and Expanding Opportunities Lead to Buy Rating for 4D Molecular Therapeutics
The company’s lead gene therapy product, 4D-150, is showing potential in revolutionizing the treatment for wet AMD with its dual transgene approach, offering comprehensive VEGF inhibition and durable ...